CA
NZ
UK
AU
IND
US
…
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Karyopharm Therapeutics is a commercial-stage oncology company developing and commercializing selective inhibitors of nuclear export; its lead therapy selinexor (XPOVIO) is approved for multiple myeloma and certain hematologic malignancies. Long-term growth drivers include label expansions and additional clinical trial readouts, continued commercialization and geographic rollout, and the broader potential of its nuclear export platform that may benefit multiple cancer indications. Investors may find the company attractive for its differentiated mechanism and the potential to extend revenues if trials and approvals progress.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -164.92M | -123.82M | -195.96M | -199.55M | -178.38M |
| Net income | -165.29M | -124.09M | -196.27M | -199.59M | -178.41M |
| Selling general administrative | 145.40M | 143.85M | 126.42M | 105.42M | 48.85M |
| Gross profit | 151.86M | 206.42M | 105.38M | 38.49M | 30.34M |
| Reconciled depreciation | 0.62M | 0.79M | 0.97M | 0.97M | 0.73M |
| Ebit | -142.20M | -98.27M | -171.85M | -189.28M | -179.88M |
| Ebitda | -139.93M | -97.77M | -168.82M | -183.90M | -175.89M |
| Depreciation and amortization | 2.28M | 0.50M | 3.03M | 5.37M | 4.00M |
| Non operating income net other | 2.28M | 0.50M | 3.03M | 5.37M | 4.00M |
| Operating income | -142.20M | -98.27M | -171.85M | -189.28M | -179.88M |
| Other operating expenses | 299.28M | 308.09M | 279.94M | 230.17M | 210.22M |
| Interest expense | 25.00M | 26.05M | 27.14M | 15.65M | 2.49M |
| Tax provision | 0.37M | 0.27M | 0.31M | 0.04M | 0.03M |
| Interest income | 2.36M | 0.58M | 2.82M | 5.42M | 4.03M |
| Net interest income | -22.64M | -25.46M | -24.32M | -10.22M | 1.53M |
| Income tax expense | 0.37M | 0.27M | 0.31M | 0.04M | 0.03M |
| Total revenue | 157.07M | 209.82M | 108.08M | 40.89M | 30.34M |
| Total operating expenses | 294.06M | 304.69M | 277.23M | 227.76M | 210.22M |
| Cost of revenue | 5.21M | 3.40M | 2.71M | 2.41M | 161.37M |
| Total other income expense net | -22.72M | -25.55M | -24.11M | -10.28M | 1.50M |
| Net income from continuing ops | -165.29M | -124.09M | -196.27M | -199.59M | -178.41M |
| Net income applicable to common shares | -165.29M | -124.09M | -196.27M | -199.59M | -178.41M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 240.44M | 358.17M | 305.31M | 313.05M | 294.96M |
| Other current assets | 11.81M | 19.82M | 2.88M | 0.56M | 1.49M |
| Total liab | 376.64M | 374.83M | 384.98M | 262.50M | 245.19M |
| Total stockholder equity | -136.21M | -16.66M | -79.67M | 50.55M | 49.77M |
| Deferred long term liab | - | - | - | - | 2.19M |
| Other current liab | 63.05M | 60.26M | 0.68M | -6.37M | 41.38M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -1487.04M | -1343.94M | -1178.65M | -1069.61M | -873.34M |
| Other liab | - | - | 215.69M | 144.58M | 75.78M |
| Other assets | 0.00M | 0.63M | 45.56M | 34.30M | 0.71M |
| Cash | 52.89M | 135.19M | 190.46M | 85.92M | 128.86M |
| Total current liabilities | 69.48M | 65.91M | 73.72M | 0.30M | 46.35M |
| Current deferred revenue | - | - | 69.12M | 0.30M | 2.34M |
| Net debt | 124.12M | 37.79M | -21.17M | 32.01M | -19.00M |
| Short term debt | 3.31M | 2.87M | 2.32M | 1.92M | 1.65M |
| Short long term debt total | 177.02M | 172.98M | 169.29M | 117.93M | 109.86M |
| Other stockholder equity | 1350.98M | 1327.91M | 1098.78M | 1119.63M | 923.14M |
| Property plant equipment | - | 1.14M | 1.64M | 2.22M | 3.05M |
| Total current assets | 233.92M | 326.75M | 258.10M | 289.54M | 273.67M |
| Long term investments | - | - | 0.00M | 24.21M | 2.02M |
| Net tangible assets | - | -16.66M | -79.67M | 50.55M | 49.77M |
| Short term investments | 139.21M | 142.78M | 38.16M | 163.32M | 133.10M |
| Net receivables | 26.96M | 47.09M | 22.50M | 12.88M | 7.86M |
| Long term debt | 170.92M | 170.10M | 169.29M | 117.93M | 109.86M |
| Inventory | 3.04M | 4.22M | 4.11M | 2.64M | 0.35M |
| Accounts payable | 3.12M | 2.77M | 1.60M | 4.45M | 0.98M |
| Accumulated other comprehensive income | -0.16M | -0.64M | 0.19M | 0.52M | -0.04M |
| Common stock total equity | - | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings total equity | - | -1343.94M | -1178.65M | -1069.61M | -873.34M |
| Non currrent assets other | 1.33M | 24.05M | 45.56M | -2.92M | 16.24M |
| Non current assets total | 6.52M | 31.42M | 47.21M | 23.51M | 21.30M |
| Capital lease obligations | 6.10M | 8.97M | 11.29M | 13.20M | 14.85M |
| Long term debt total | - | - | - | 117.93M | 109.86M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -104.14M | 147.55M | -53.54M | 78.66M | -105.30M |
| Change to liabilities | -8.37M | 13.41M | 15.63M | 5.21M | 9.88M |
| Total cashflows from investing activities | -104.26M | 141.84M | -53.69M | 78.45M | -107.66M |
| Net borrowings | - | - | - | - | 166.88M |
| Total cash from financing activities | 193.74M | 73.65M | 172.08M | 124.31M | 316.11M |
| Change to operating activities | -15.96M | -8.97M | 9.77M | 7.56M | 9.24M |
| Net income | -165.29M | -124.09M | -196.27M | -199.59M | -178.41M |
| Change in cash | -60.56M | 108.32M | -41.57M | 11.95M | 49.25M |
| Begin period cash flow | 197.44M | 89.12M | 130.69M | 118.74M | 69.49M |
| End period cash flow | 136.88M | 197.44M | 89.12M | 130.69M | 118.74M |
| Total cash from operating activities | -149.55M | -107.12M | -160.23M | -190.82M | -159.12M |
| Issuance of capital stock | 189.76M | 9.90M | 161.78M | 46.19M | 145.71M |
| Depreciation | 0.62M | 0.79M | 0.97M | 0.97M | 0.73M |
| Other cashflows from investing activities | - | -5.50M | - | 78.66M | -105.30M |
| Change to inventory | -0.12M | -1.46M | -2.63M | -0.35M | -0.35M |
| Change to account receivables | -5.08M | -9.62M | -5.02M | -7.86M | -7.86M |
| Sale purchase of stock | 3.98M | 3.75M | 10.31M | 4.50M | 3.52M |
| Other cashflows from financing activities | 3.98M | 63.74M | 10.31M | 78.11M | 170.40M |
| Change to netincome | 35.12M | 37.03M | 24.22M | 15.29M | 17.27M |
| Capital expenditures | 0.12M | 5.71M | 0.14M | 0.21M | 2.36M |
| Change receivables | -5.08M | -9.62M | -5.02M | -7.86M | - |
| Cash flows other operating | -6.42M | -25.52M | -6.62M | -10.31M | -10.04M |
| Cash and cash equivalents changes | -60.07M | 108.37M | -41.84M | 11.93M | 49.33M |
| Change in working capital | -19.99M | -23.19M | 1.36M | -13.31M | -0.17M |
| Stock based compensation | 35.40M | 29.78M | 24.41M | 15.29M | 17.27M |
| Other non cash items | -0.29M | 8.13M | 8.40M | 7.19M | 1.42M |
| Free cash flow | -149.67M | -112.83M | -160.38M | -191.03M | -161.48M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics Inc |
-0.22 24.76% |
0.66 | - | - | 0.96 | 12.05 | 0.86 | -1.06 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Richard A. Paulson M.B.A. | Pres, CEO & Director | 1967 |
| Dr. Sharon Shacham M.B.A., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 1970 |
| Mr. Michael P. Mason CPA, M.B.A. | Exec. VP, CFO & Treasurer | 1975 |
| Mr. Ran Frenkel R.Ph., RPh | Global Head of Clinical Operations | 1969 |
| Dr. Mansoor Raza Mirza M.D. | Clinical Consultant, Member of Scientific Advisory Board & Independent Director | 1961 |
| Mr. Cameron Peters | VP of Fin., Assistant Treasurer & Principal Accounting Officer | 1960 |
| Mr. Pierre S. Sayad M.S., Ph.D. | VP of Global Medical & Scientific Affairs | NA |
| Ms. Elhan Webb C.F.A. | Sr. VP of Investor Relations | NA |
| Mr. Michael J. Mano J.D. | Sr. VP, Gen. Counsel & Sec. | 1977 |
| Mr. James Accumanno J.D. | Chief Compliance Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...